Drug Type Proteolysis-targeting chimeras |
Synonyms- |
Target |
Mechanism Akt-1 inhibitors(Serine/threonine-protein kinase AKT inhibitors), Akt-2 inhibitors(Serine/threonine-protein kinase AKT2 inhibitors), Akt-3 inhibitors(Serine/threonine-protein kinase AKT3 inhibitors) + [1] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC58H81ClN10O7S |
InChIKeyQUWWUNJGSUEYJK-PYSDWBMZSA-N |
CAS Registry2376137-31-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | US | 02 Dec 2021 | |
Neoplasms | Preclinical | US | 02 Dec 2021 |